Drug Profile
Research programme: cannabis extract therapeutics - Cannabis Science
Alternative Names: CBIS GAP-001; CBIS LC-001; CBIS OBLD-001; CBIS OCD-001; CBIS PC-001; CBIS PPC-001; CBIS PS-001; CBIS SD-001; CBIS SSA-001; CBIS-OS-001; CBIS-PTSD-001; CS NEURO 1; CS-S/BCC-1; CS-TATI-1; Phytocannabinoid-based pharmaceutical products - Cannabis ScienceLatest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator Cannabis Science
- Developer Cannabis Science; Italian Institute for Health and Science on Ageing
- Class Analgesics; Anti-inflammatories; Antianaemics; Antineoplastics; Antiretrovirals; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Skin disorder therapies; Sleep disorder therapies
- Mechanism of Action Cannabinoid receptor modulators; Human immunodeficiency virus tat gene product inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Adult respiratory distress syndrome; Anaemia; Anxiety disorders; Arthritis; Attention-deficit hyperactivity disorder; Autistic disorder; Cancer; Dyskinesias; Fibromyalgia; HIV infections; Kaposi's sarcoma; Lung cancer; Neurological disorders; Neuropathic pain; Obsessive-compulsive disorders; Pain; Pancreatic cancer; Post-traumatic stress disorders; Prostatitis; Respiratory tract disorders; Rheumatic disorders; Sickle cell anaemia; Skin cancer; Skin disorders; Sleep disorders; Wounds
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Anaemia in USA
- 28 Sep 2023 No recent reports of development identified for preclinical development in Anxiety-disorders in USA
- 28 Sep 2023 No recent reports of development identified for preclinical development in Arthritis in USA